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Abstract
Tumor recognition by immune effector cells is mediated by antigen receptors and a variety of adhesion and costimulatory
molecules. The evidence accumulated since the identification of CD155 and CD112 as ligands for DNAM-1 in humans and
mice has suggested that the interactions between DNAM-1 and its ligands play an important role in T cell– and natural killer
(NK) cell–mediated recognition and lysis of tumor cells. We have previously demonstrated that methylcholanthrane (MCA)
accelerates tumor development in DNAM-1–deficient mice, and the Cd155 level on MCA-induced tumors is significantly
higher in DNAM-1–deficient mice than in wild-type (WT) mice. By contrast, Cd112 expression on the tumors is similar in WT
and DNAM-1-deficient mice, suggesting that CD155 plays a major role as a DNAM-1 ligand in activation of T cells and NK
cells for tumor immune surveillance. To address this hypothesis, we examined MCA-induced tumor development in CD155-
deficient mice. Unexpectedly, we observed no significant difference in tumor development between WT and CD155-
deficient mice. Instead, we found that Cd112 expression was significantly higher in the MCA-induced tumors of CD155-
deficient mice than in those of WT mice. We also observed higher expression of DNAM-1 and lower expression of an
inhibitory receptor, TIGIT, on CD8+ T cells in CD155-deficient mice. These results suggest that modulation of the expression
of receptors and CD112 compensates for CD155 deficiency in immune surveillance against MCA-induced tumors.
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Introduction
Cancer immune surveillance to suppress tumor development is
an important host protection process. Several immune effector cell
types and secreted cytokines play a critical role in this process.
Among them, cytotoxic T lymphocytes (CTL) and natural killer
(NK) cells are major players in cell-mediated immunity against
tumors [1,2]. Interaction of cell surface receptors on CTL and NK
cells with their respective ligands expressed on tumors activates the
CTL and NK cells [2,3], resulting in their secretion of cytokines
and cytotoxicity against tumors [4,5].
The leukocyte adhesion molecule DNAX accessory molecule-1
(DNAM-1, also known as CD226) is a member of the immuno-
globulin (Ig) superfamily and is constitutively expressed on most
CD4+ and CD8+ T cells, NK cells, monocytes, and macrophages
[6]. The poliovirus receptor (PVR) CD155 and another member
of the same family, CD112 (PVR-related family 2 [PRR-2], also
called nectin-2), are the ligands of DNAM-1 in humans and mice
[7–9]. Interactions between DNAM-1 on NK cells and CD8+ T
cells and CD112 and CD155 on tumor cells augment cell-
mediated cytotoxicity and cytokine production [7,8].
CD155 and CD112 are present on various types of epithelial
and endothelial cells in many tissues [10,11]. A number of studies
have demonstrated that CD155 and CD112 are overexpressed on
certain hematopoietic and nonhematopoietic tumors [12–17],
suggesting that DNAM-1 ligand expression might be induced by
tumorigenesis and might stimulate CTL- and NK cell–mediated
tumor immunity. Of note, CD155 and CD112 also bind TIGIT
(T cell immunoreceptor with Ig and ITIM [immunoreceptor
tyrosine-based inhibitory motif] domains), which is expressed on T
cells and NK cells and mediates an inhibitory signal (either directly
or indirectly) in these cells [18,19]. CD155 also binds an
immunoreceptor, CD96 (also called T cell-activated increased
late expression [TACTILE]), that is expressed on both activated T
cells and NK cells [20–22]. Taken together, the available data
suggest that CD155 might be a double-edged sword balancing
tumor growth and elimination.
We have previously demonstrated that the chemical carcinogens
methylcholanthrane (MCA) and 7,12-dimethylbenz[a]anthracene
(DMBA) result in significantly greater development of fibrosarco-
ma and papilloma, respectively, in DNAM-1–deficient mice than
in wild-type (WT) mice [23]. Interestingly, we found that although
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Cd155 expression on MCA-induced fibrosarcomas was signifi-
cantly higher in DNAM-1–deficient mice than in WT mice,
Cd112 expression was similar, suggesting that CD155, rather than
CD112, is the tumor ligand involved in DNAM-1–mediated
immune surveillance against MCA-induced fibrosarcoma. In the
present study, we used CD155-deficient mice to examine the role
of CD155 on MCA-induced fibrosarcomas in tumor immune
surveillance.
Materials and Methods
Mice
C57BL/6N and BALB/c mice were purchased from CLEA
(Tokyo, Japan). CD155-deficient C57BL/6N and BALB/c mice
were described previously [24]; they were additionally backcrossed
twice with C57BL/6N and BALB/c mice, respectively (a total of
12 generations). All mice were housed and bred under specific-
pathogen-free conditions at the Animal Resource Center of the
University of Tsukuba. Animal experiments were carried out in a
humane manner after receiving approval from the Animal
Experiment Committee of the University of Tsukuba
(Approval No.: 10-237, 11-231, 12-231), and in accordance with
Fundamental Guideline for Proper Conduct of Animal Experi-
ment and Related Activities in Academic Research Institutions
under the Jurisdiction of the Ministry of Education, Culture,
Sports, Science and Technology, and Japanese Act on Welfare
and Management of Animals (No.105).
Flow cytometry
CD4+ T, CD8+ T, and NK cells from peripheral blood were
analyzed using an LSRFortessa flow cytometer (BD Biosciences,
San Jose, CA). The anti-DNAM-1 monoclonal antibody (mAb)
TX42 (rat IgG2a) was generated in our laboratory [13]. All other
antibodies for flow cytometry analyses were purchased from BD
Biosciences. CD8+ T cells were purified by magnetic separation
from spleen cells on a Mini-MACS system (Miltenyi Biotec,
Bergisch Gladbach, Germany). Purified CD8+ T cells were
cultured in the presence of 20 ng/ml exogenous IL-2 (BD
Biosciences) in a 24-well plate coated with 1 mg/ml of anti-
CD3e mAb (BD Biosciences). The cells were harvested at various
time points, and the cell surface molecules were analyzed by flow
cytometry. Antibodies against TIGIT and CD96 were from
eBioscience (San Diego, CA) and R&D Systems (Minneapolis,
MN), respectively. Cell staining and flow cytometry were
performed according to standard procedures. The CellQuest
(BD Biosciences) and FlowJo (Tree Star, Inc., Ashland, OR)
programs were used for data acquisition and analysis.
Tumor growth assay and survival of mice
Groups of 10–20 WT or CD155-deficient male mice (8–12
week-old) were injected subcutaneously (s.c.) in the back with 5 or
100 mg (as specified in the figure legends) MCA (Sigma-Aldrich,
St. Louis, MO) dissolved in 0.1 ml corn oil (Sigma-Aldrich) after
anesthetization (7:3 mixture of polyethylene glycol and isoflurane).
Figure 1. MCA-induced tumor development in WT and CD155-deficient mice. (A, B) WT (n=18 and 16, respectively) or CD155-deficient (KO;
n= 19 and 20, respectively) C57BL/6N mice were injected s.c. with 5 mg (A) or 100 mg (B) methylcholanthrane (MCA) on day 0. (C) WT (n= 15) or KO
(n=10) BALB/c mice were injected s.c. with 5 mg MCA on day 0. Tumor size in each mouse was measured once a week. Tumor size (top) and survival
data (bottom) are shown.
doi:10.1371/journal.pone.0112415.g001
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Figure 2. Relative cytokine mRNA levels in MCA-induced tumors. (A, B) Fibrosarcomas induced by 5 mg MCA in WT or CD155-deficient (KO)
C57BL/6N (A) or BALB/c (B) mice were resected from each mouse and subjected to quantitative qRT-PCR for transcripts of the indicated cytokines.
Horizontal bars represent means and error bars represent means 6 SEM. P Values for Student’s t test are shown.
doi:10.1371/journal.pone.0112415.g002
Figure 3. Relative Cd112 mRNA levels in organs and MCA-induced tumors. (A) Tissues from WT (n= 3) or CD155-deficient (KO; n= 3) mice
were subjected to quantitative qRT-PCR for Cd112. Error bars represent means 6 SD. (B, C) Fibrosarcomas induced in WT or CD155-deficient C57BL/
6N (B) or BALB/c (C) mice by 5 mg MCA were resected from each mouse and subjected to qRT-PCR for Cd112. Horizontal bars represent means and
error bars represent means 6 SEM. P Values for Student’s t test are shown.
doi:10.1371/journal.pone.0112415.g003
CD112 Expression in CD155-Deficient Tumor
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Mice were examined at least once a week for tumor size with a
caliper square as previously described [13]. Mouse survival was
closely monitored 3 times per week during the experimental period
and the humane endpoint was applied for euthanization by excess
anesthetization.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from fibrosarcomas and naive tissues
with the Isogen reagent (Nippon Gene, Tokyo, Japan). For reverse
transcription, we used 2 mg of total RNA and a High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad,
CA) in a final volume of 20 ml. qRT-PCR was performed on a
7500 FAST Real-Time PCR System (Applied Biosystems) with
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen,
Grand Island, NY). The primers were as follows: Ifng, 59-TCA-
AGTGGCATAGATGTGGAAGAA-39 (forward) and 59-TGGC-
TCTGCAGGATTTTCATG-39 (reverse); Il1b, 59-TGAAGCAG-
CTATGGCAACTG-39 (forward) and 59-CAGGTCAAAGGTT-
TGGAAGC-39 (reverse); Il12b, 59-GGAGACCCTGCCCATTG-
AACT-39 (forward) and 59-CAACGTTGCATCCTAGGATCG-3
(reverse); Il10, 59-GCTGGACAACATACTGCTAACC-39 (for-
ward) and 59-ATTTCCGATAAGGCTTGGCAA-39 (reverse);
Cd112d, 59-CTCTGTGGATCGAATGGTCA-39 (forward) and
59-GGCAGCGATAATACCTCCAA-39 (reverse); Cd226, 59-T-
CGCTCAGAGGCCATTACAG-39 (forward) and 59-CCCTG-
GGCTCTTTAAGTGGAA-39 (reverse); Tigit, 59-CTGATACA-
GGCTGCCTTCCT-39 (forward) and 59-TGGGTCACTTCAG-
CTGTGTC-39 (reverse); Cd96, 59-TCCCCAATATGGCCTCT-
ACTG-39 (forward) and 59-GACTGTAGTCTTGATGCCTT-
CTG-3 (reverse). The level of the b-actin or Cd2 transcripts were
measured as internal controls. b-actin, 59-GGCTGTATTCCC-
CTCCATCG-39 (forward) and 59-CCAGTTGGTAACAATGC-
CATGT-39 (reverse); Cd2, 59- TGGTAACTCATGTTCTTC-
TGG-39 (forward) and 59- GTAATGGTGTATGGCACAA-
ATG-39 (reverse). PCR conditions were as follows: an initial
denaturation step at 95uC for 10 min, followed by 40 cycles at
Figure 4. Expression of CD155 ligands on resting and activated T cells from WT and CD155-deficient mice. (A) Peripheral blood
lymphocytes from WT (n= 3) or CD155-deficient (KO; n= 3) C57BL/6N mice were stained with anti-DNAM-1, anti-TIGIT, or anti-CD96 antibodies (WT;
blue lines, KO; red lines) or control antibodies (WT; light blue lines, KO; pink lines), and analyzed by flow cytometry. The numbers (WT; in blue, KO; in
red) indicate the mean fluorescence intensity (MFI) of DNAM-1, TIGIT, and CD96 staining. Representative data are shown. (B) MFI was used to analyze
DNAM-1 expression on CD4+ T, CD8+ T, and NK cells as in (A). Error bars represent means 6 SD. (C) CD8+ T cells purified from spleen were activated
with anti-CD3 antibody and IL-2 for the indicated number of days. Cells were stained and analyzed by flow cytometry, as described in (A). (D) The
expression of DNAM-1, TIGIT, and CD96 on CD8+ T cells is shown as MFI as in (C). *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0112415.g004
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95uC for 15 s and 60uC for 1 min. Data were analyzed by the
22DDCt method. All values were determined in triplicate.
Statistics
The survival of mice was analyzed by the Kaplan–Meier
survival method followed by the log-rank test. All other statistical
analyses were performed using the unpaired Student’s t test. P,
0.05 was considered statistically significant.
Results
MCA-induced tumor development is similar in WT and
CD155-deficient mice
To examine the effect of CD155 on MCA-induced fibrosarco-
ma in tumor immune surveillance, WT and CD155-deficient mice
in the C57BL/6N background were injected with MCA.
Unexpectedly, both groups showed a similar course of fibrosar-
coma development 80–250 days after MCA injection, and their
survival rates were similar (Fig. 1A, B). Similar results were
obtained for WT and CD155-deficient mice in the BALB/c
background (Fig. 1C). These results suggest that, although
DNAM-1 expressed on T cells and NK cells plays an important
role in immune surveillance against MCA-induced fibrosarcoma,
the counterpart of DNAM-1 on the fibrosarcoma may not be
CD155 alone.
Expression of cytokine genes is similar in tumors from WT
and CD155-deficient mice
Cytokines expressed in immune cells infiltrating tumor tissues
are involved in tumor immune responses. Because there was no
Figure 5. A hypothetical model for interactions between activating/inhibitory receptors DNAM-1, TIGIT and CD96 on T or NK cells
and CD155/CD112 ligands expressed on MCA-induced fibrosarcoma in WT or CD155-deficient mice. (A) DNAM-1 and TIGIT bind to both
of CD155 and CD112, while CD96 interacts with CD155 only. Each receptor-ligand interaction transduces either activating or inhibitory signal, as
shown by the red or blue arrow, respectively. The modulation of the receptors and ligand expression on CD155-deficient (KO) fibrosarcoma are
indicated. (B) The sums of the activating and inhibitory signals are similar between WT and KO.
doi:10.1371/journal.pone.0112415.g005
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difference in MCA-induced tumor development between WT and
CD155-deficient mice, we next investigated cytokine expression in
tumor tissues from the two types of mice. qRT-PCR revealed that
the levels of mRNA for the proinflammatory cytokines Ifng, Il1b,
and Il12b and the anti-inflammatory cytokine Il10 in fibrosarco-
mas induced by 5 mg MCA were similar in WT and CD155-
deficient mice in both C57BL/6N and BALB/c backgrounds
(Fig. 2). These results suggest that cytokine expression levels in
immune cells infiltrating into tumors were similar in CD155-
defficient mice and WT mice.
Cd112 expression is increased in MCA-induced
fibrosarcoma in CD155-deficient mice
We next examined the expression of Cd112 in MCA-induced
fibrosarcoma in WT and CD155-defficient mice. In naı¨ve
C57BL/6N mice, Cd112 expression was similar in several organs,
including the skin, in WT and CD155-deficient mice (Fig. 3A).
However, in MCA-induced fibrosarcoma, Cd112 expression was
significantly higher in CD155-deficient mice than in WT mice
(Fig. 3B). Similar results were obtained for CD155-deficient mice
in the BALB/c background (Fig. 3C). These results suggest that
Cd112 expression is upregulated in MCA-induced fibrosarcoma in
CD155-deficient mice during the transformation.
DNAM-1 and CD96 expressions on resting T cells are
increased in CD155-deficient mice
A previous report demonstrated that DNAM-1 expression on T
cells was significantly higher in CD155-deficient mice than in WT
mice [25]. Consistent with this, our flow cytometry analysis
demonstrated significantly higher expression of DNAM-1 on
peripheral blood CD4+ and CD8+ T cells (Fig. 4A). Fluorescence
intensity analysis confirmed a significant increase in DNAM-1
expression on CD4+ and CD8+ T cells (Fig. 4B). At the same time,
we also analyzed the expressions of TIGIT and CD96 on those cells
and found that CD96 but not TIGIT expression on CD4+ and
CD8+ T cells was also significantly higher in CD155-deficient mice
than in WT mice. As to NK cells, however, we did not observe a
difference of these molecules’ expression between in WT and in
CD155-deficient mice. TIGIT was markedly expressed on NK cells
compared to CD4+ and CD8+ T cells, although there was no
significant difference between WT and CD155-deficient mice.
Receptor modulation by CD8+ T cell activation
As CD155 binds CD96, TIGIT, and DNAM-1, we examined
the expression of these receptors on activated CD8+ T cells. CD8+
T cells from the spleens of WT and CD155-deficient mice were
stimulated with anti-CD3 mAb in the presence of IL-2. DNAM-1
and CD96 expression was significantly higher on resting CD155-
deficient CD8+ T cells than on resting WT CD8+ T cells, whereas
TIGIT expression was not detected (Fig. 4C, D). Activated CD8+
T cells increased expression of TIGIT on both WT and CD155-
deficient CD8+ T cells after stimulation. Upon stimulation, the
levels of DNAM-1 and CD96 were still significantly higher on
CD155-deficient than on WT CD8+ T cells, whereas TIGIT
expression was significantly lower on CD155-deficient CD8+ T
cells than on WT CD8+ T cells (Fig. 4C, D).
To analyze the expressions of DNAM-1, TIGIT, and CD96 on
tumor-resident immune cells, fibrosarcomas induced by 5 mg
MCA in WT or CD155-deficient mice were resected and
subjected to quantitative RT-PCR by using Cd2 expression,
which is specifically expressed on T cells and NK cells, but not on
non-hematopoietic cells, for normalization. The average tumor
size and time points of resection after MCA injection were
comparable between two groups. However, we did not observe
different expression levels of those receptors in tumors between
WT and CD155-deficient mice (Fig. S1).
Discussion
CD155 and CD112 are involved in tumor immune surveillance,
because ectopic expression of CD155 or CD112 on tumors can
induce cell-mediated cytotoxicity [13]. Although the binding
affinities of DNAM-1 to CD155 and CD112 are similar [8],
CD155 rather than CD112 appears to play a predominant role in
DNAM-1-dependent NK cell triggering [7]. CD112, but not
CD155, mediates not only heterophilic but also homophilic
binding. This ability may adversely affect DNAM-1 binding to
CD112, suggesting that DNAM-1 may prefer CD155 to CD112 as
a physiological ligand [8,26].
Our previous study demonstrated that the development of
MCA-induced fibrosarcoma and DMBA-induced papilloma was
enhanced in DNAM-1-deficient mice, suggesting that DNAM-1
on T cells, NK cells, or both plays an important role in immune
surveillance against DNAM-1 ligand–expressing tumors [23]. In
this study, we used CD155-deficient mice to examine whether
CD155 on MCA-induced fibrosarcoma plays a reciprocal role in
tumor immunity. Unexpectedly, however, we found that MCA-
induced tumors developed similarly in WT and CD155-deficient
mice. We suggest several possible explanations of why the absence
of CD155 on tumors did not affect tumor immunity (Fig. 5). First,
Cd112 expression in fibrosarcomas was significantly higher in
CD155-deficient mice than in WT mice, suggesting that DNAM-1
interaction with CD112 compensated for the loss of the DNAM-
1–CD155 interaction. CREB and c-Jun may regulate Cd112
transcription [27] and are often activated in cancers [28,29]. The
relative amounts of Cd112 mRNA are higher in poorly
differentiated gastric cancer than in normal gastric tissue [13].
Second, DNAM-1 expression was significantly upregulated on
CD4+ and CD8+ T cells from CD155-deficient mice, consistent
with a previous report [25]. DNAM-1 upregulation in CD8+ T
cells was independent of antigen-driven activation because it was
already observed in resting T cells, but it was still upregulated after
stimulation. We also found that, although TIGIT expression was
upregulated after stimulation with anti-CD3 mAb in both WT and
CD155-deficient CD8+ T cells, it was significantly lower in
CD155-deficient cells than in WT cells. TIGIT is an inhibitory
receptor that binds to both CD155 and CD112 [18]. Thus,
upregulated expression of the activating receptor DNAM-1 and
downregulated expression of the inhibitory receptor TIGIT should
be favorable for cytotoxicity mediated by T cells, NK-cells, or both
against tumors with upregulated CD112, even if the affinity of
CD112 for binding DNAM-1 or TIGIT is lower than that of
CD155. CD96 expression was also significantly higher on CD155-
deficient CD8+ T cells than WT cells. Recent evidence indicates
that CD96, which binds CD155 but not CD112, negatively
regulates tumor immunity and cytokine secretion by NK cells [21].
Thus, the absence of CD155 on tumors would downregulate
CD96-mediated NK cell inhibition, resulting in an increase in
cytotoxicity against CD155-deficient tumors. It remains unclear
how the expression of DNAM-1, TIGIT, CD96, and CD112 is
modulated in CD155-deficient mice. A better understanding of the
mechanisms that regulate the levels of these molecules may
provide new insights into possible ways to improve cancer
immunotherapy.
In contrast to the peripheral blood lymphocytes, we did not
observe any different expression levels of DNAM-1, TIGIT, and
CD96 in tumors after normalization by Cd2 expression between
CD112 Expression in CD155-Deficient Tumor
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WT and CD155-deficient mice. It is unclear at present how these
results can be explained. However, it is possible that, during tumor
development for more than 100 days, immune cell activation
might be modified. For example, myeloid-derived suppressor cells
(MDSC) in tumors tissues suppress both innate and adaptive
immunities by secretion of various cytokines [30], which might
affect the expression of the cell surface molecules.
We have previously shown that abrogating DNAM-1 activity on
CD8+ T cells results in development of milder graft-versus-host
disease (GVHD) [31,32]. On the other hand, Seth et al. reported
that the absence of CD155 aggravated acute GVHD, which is
mainly caused by CD4+ T cells [33]. Although there are
differences in the experimental settings between the two GVHD
models, these observations and the results of our current study
indicate that phenotypes of CD155 and DNAM-1 deficiencies are
not two sides of the same coin.
Supporting Information
Figure S1 Relative DNAM-1, TIGIT, and CD96 mRNA levels
in MCA-induced tumors. Fibrosarcomas induced by 5 mg MCA in
WT or CD155-deficient (KO) C57BL/6N mice were resected and
subjected to quantitative RT-PCR for the expression of transcripts
of the indicated receptors as described in Materials and Methods.
(A) Tumor size, days of resection after MCA injection, and relative
expressions of the transcripts are shown. (B) Relative expressions of
indicated receptors are shown. Horizontal bars represent means
and error bars represent means 6 SEM. P Values for Student’s t
test are shown.
(PPT)
Material S1 The ARRIVE Guidelines Checklist. We followed
the ARRIVE (Animal Research: Reporting of In Vivo Exper-
iments) guidelines and the ARRIVE Checklist is available as
supporting information.
(PDF)
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